The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 756K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

8 articles for KJ Milliner


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Purine derivatives as competitive inhibitors of human erythrocyte membrane phosphatidylinositol 4-kinase.EBI
Smith Kline & French Research
The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2.EBI
Glaxosmithkline
The discovery of SB-435495. A potent, orally active inhibitor of lipoprotein-associated phospholipase A(2) for evaluation in man.EBI
Glaxosmithkline
Potent, orally active inhibitors of lipoprotein-associated phospholipase A(2): 1-(biphenylmethylamidoalkyl)-pyrimidones.EBI
Glaxosmithkline
1-(Arylpiperazinylamidoalkyl)-pyrimidones: orally active inhibitors of lipoprotein-associated phospholipase A(2).EBI
Glaxosmithkline
The identification of a potent, water soluble inhibitor of lipoprotein-associated phospholipase A2.EBI
Glaxosmithkline
N-1 substituted pyrimidin-4-ones: novel, orally active inhibitors of lipoprotein-associated phospholipase A2.EBI
Smithkline Beecham Pharmaceuticals
2-(Alkylthio)pyrimidin-4-ones as novel, reversible inhibitors of lipoprotein-associated phospholipase A2.EBI
Smithkline Beecham Pharmaceuticals